Log in

NASDAQ:OCULOcular Therapeutix Stock Price, Forecast & News

$6.84
-0.38 (-5.26 %)
(As of 05/26/2020 04:00 PM ET)
Add
Compare
Today's Range
$6.77
Now: $6.84
$7.57
50-Day Range
$4.78
MA: $5.87
$7.22
52-Week Range
$2.38
Now: $6.84
$8.12
Volume1.42 million shs
Average Volume1.09 million shs
Market Capitalization$364.98 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert), which has completed two Phase III clinical trials for the treatment of post-surgical ocular pain and inflammation, and allergic conjunctivitis; and DEXTENZA, which is in Phase III clinical trials for the treatment of dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert), which is in Phase III clinical trials for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant, which is in Phase I clinical trials for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant, which is in Phase I clinical trials for the treatment of wet age-related macular degeneration(AMD). Its various preclinical programs include OTX- BPI for the treatment of acute ocular pain; OTX-BDI to treat post-operative Pain, and inflammation and bacterial infection; OTX-CSI to treat dry-eye disease; and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Read More
Ocular Therapeutix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.6Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.24 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OCUL
CUSIPN/A
Phone781-357-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.23 million
Book Value($0.20) per share

Profitability

Net Income$-86,370,000.00
Net Margins-1,430.64%

Miscellaneous

Employees161
Market Cap$364.98 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

How has Ocular Therapeutix's stock been impacted by COVID-19 (Coronavirus)?

Ocular Therapeutix's stock was trading at $5.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, OCUL stock has increased by 27.9% and is now trading at $6.84. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ocular Therapeutix?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ocular Therapeutix.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Ocular Therapeutix.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix Inc (NASDAQ:OCUL) issued its quarterly earnings data on Friday, May, 8th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.40) by $0.01. The biopharmaceutical company had revenue of $2.61 million for the quarter, compared to analysts' expectations of $2.66 million. Ocular Therapeutix had a negative return on equity of 6,659.51% and a negative net margin of 1,430.64%. View Ocular Therapeutix's earnings history.

What guidance has Ocular Therapeutix issued on next quarter's earnings?

Ocular Therapeutix issued an update on its first quarter 2020 After-Hours earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.6-2.6 million, compared to the consensus revenue estimate of $3.09 million.

What price target have analysts set for OCUL?

6 analysts have issued 12-month target prices for Ocular Therapeutix's stock. Their forecasts range from $5.00 to $11.00. On average, they expect Ocular Therapeutix's share price to reach $8.60 in the next year. This suggests a possible upside of 25.7% from the stock's current price. View analysts' price targets for Ocular Therapeutix.

Has Ocular Therapeutix been receiving favorable news coverage?

News coverage about OCUL stock has trended positive this week, according to InfoTrie Sentiment. The research firm scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ocular Therapeutix earned a news sentiment score of 2.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the near future. View the latest news aboutOcular Therapeutix.

Who are some of Ocular Therapeutix's key competitors?

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), Celgene (CELG), Inovio Pharmaceuticals (INO), Omeros (OMER), Gilead Sciences (GILD), Cara Therapeutics (CARA), Exelixis (EXEL) and TG Therapeutics (TGTX).

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the following people:
  • Mr. Antony Mattessich, Pres, CEO & Director (Age 53, Pay $907.55k)
  • Ms. Patricia Kitchen, Chief Operations Officer (Age 42, Pay $639.64k)
  • Dr. Michael H. Goldstein, Chief Medical Officer (Age 53, Pay $550.76k)
  • Mr. Donald Notman Jr., Chief Financial Officer
  • Dr. Peter K. Jarrett Ph.D., Chief Scientific Officer (Age 63)

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.44%), Deltec Asset Management LLC (3.94%), Ikarian Capital LLC (2.92%), State Street Corp (1.54%), Geode Capital Management LLC (1.23%) and EAM Investors LLC (0.65%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein, Opaleye Management Inc, Richard L Md Lindstrom and Summer Road Llc. View institutional ownership trends for Ocular Therapeutix.

Which major investors are selling Ocular Therapeutix stock?

OCUL stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Deltec Asset Management LLC, UBS Group AG, Levin Capital Strategies L.P., Quilter Plc, and Wells Fargo & Company MN. View insider buying and selling activity for Ocular Therapeutix.

Which major investors are buying Ocular Therapeutix stock?

OCUL stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, EAM Investors LLC, EAM Global Investors LLC, Invesco Ltd., State Street Corp, Geode Capital Management LLC, Raymond James & Associates, and Fred Alger Management LLC. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman, Jeffrey S Heier, Kevin F Hanley, Leslie J Williams, Michael H Goldstein, Opaleye Management Inc, Richard L Md Lindstrom, and Summer Road Llc. View insider buying and selling activity for Ocular Therapeutix.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $6.84.

How big of a company is Ocular Therapeutix?

Ocular Therapeutix has a market capitalization of $364.98 million and generates $4.23 million in revenue each year. The biopharmaceutical company earns $-86,370,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Ocular Therapeutix employs 161 workers across the globe.

What is Ocular Therapeutix's official website?

The official website for Ocular Therapeutix is www.ocutx.com.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.